SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
SANTA CLARA, Calif., Sept. 15, 2016 -- Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today that the Company will present at the Ladenburg Thalmann Healthcare Conference in New York, NY.
Event: Ladenburg Thalmann 2nd Annual Healthcare Conference
Date: Tuesday, September 27th, 2016
Time: 1:00 p.m. ET
An audio webcast of the Company’s presentation will be available online at www.miramarlabs.com/investors. A replay of the presentation will be available for 90 days.
Investors who are not attending the conference but would like to schedule a one-on-one meeting with Miramar management may do so by contacting Chris Nardo at The Ruth Group at [email protected].
About Miramar Labs:
Miramar Labs, Inc.® is a global medical device company dedicated to bringing innovative and clinically proven applications to treat unmet needs in the aesthetic marketplace. Supported by rigorous clinical research, Miramar Labs is focused on addressing medical conditions for which there are significant unmet clinical needs. The company’s first priority is the treatment of bothersome underarm sweat, an issue that hundreds of millions of people deal with daily. The miraDry® procedure has an established safety and efficacy profile with over 70,000 patients treated worldwide. Physicians and patients are encouraged to visit www.miramarlabs.com or www.miradry.com for additional information.
Contact: Investors: Brigid Makes Sr. Vice President & CFO Phone: 408.579.8700 Email: [email protected] Nick Laudico or Zack Kubow The Ruth Group 646-536-7030 / 7020 [email protected] [email protected]
